Our research suggests that 1-benzyl-3-(5’-hydroxymethyl-2’-furyl)indazole (YC-1) activates sGC of human platelet by the NO-independent mechanism, and exerts its antiplatelet effect through the sGC/cGMP pathway. To further explore the structure-activity relationships of YC-1 analogs, 1-benzyl-3-(5-methyl-2-furyl)indazole was synthesized and demonstrated antiplatelet activity comparable to that of YC-1. Encourage by this result, we are intending to synthesize its pyrazole analogs -- 1-(substituted benzyl)-3-(5-methyl-2-furyl)-5-phenylpyrazoles. The antiplatelet activities of the target compounds were examined. Some of them exhibit significantly inhibitory effect against collagen- and ADP-induced platelet aggregation.?
